Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. The company offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Aphria Inc. Tilray, Inc. was incorporated in 2018 and is based in New York, New York.
IPO Year: 2018
Exchange: NASDAQ
Website: tilray.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/5/2024 | $2.25 → $2.75 | Neutral | Alliance Global Partners |
| 11/2/2022 | $3.90 | Mkt Perform | Bernstein |
| 7/29/2022 | $3.00 | Hold → Sell | The Benchmark Company |
| 3/4/2022 | $9.00 | Hold → Buy | Canaccord Genuity |
| 1/11/2022 | $7.40 → $6.90 | Neutral | Cantor Fitzgerald |
| 1/7/2022 | $11.80 → $7.40 | Neutral | Cantor Fitzgerald |
| 11/18/2021 | $10.00 | Underweight | Barclays |
| 11/1/2021 | $18.00 → $11.80 | Overweight → Neutral | Cantor Fitzgerald |
| 10/8/2021 | $14.00 → $12.00 | Neutral | CIBC |
| 9/17/2021 | $19.00 → $18.00 | Overweight | Cantor Fitzgerald |
4 - Tilray Brands, Inc. (0001731348) (Issuer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)
3 - Tilray Brands, Inc. (0001731348) (Issuer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)
4 - Tilray Brands, Inc. (0001731348) (Issuer)
Alliance Global Partners reiterated coverage of Tilray with a rating of Neutral and set a new price target of $2.75 from $2.25 previously
Bernstein initiated coverage of Tilray with a rating of Mkt Perform and set a new price target of $3.90
The Benchmark Company downgraded Tilray from Hold to Sell and set a new price target of $3.00
Canaccord Genuity upgraded Tilray from Hold to Buy and set a new price target of $9.00
Cantor Fitzgerald reiterated coverage of Tilray with a rating of Neutral and set a new price target of $6.90 from $7.40 previously
Cantor Fitzgerald reiterated coverage of Tilray with a rating of Neutral and set a new price target of $7.40 from $11.80 previously
Barclays initiated coverage of Tilray with a rating of Underweight and set a new price target of $10.00
Cantor Fitzgerald downgraded Tilray from Overweight to Neutral and set a new price target of $11.80 from $18.00 previously
CIBC reiterated coverage of Tilray with a rating of Neutral and set a new price target of $12.00 from $14.00 previously
Cantor Fitzgerald reiterated coverage of Tilray with a rating of Overweight and set a new price target of $18.00 from $19.00 previously